Cero Therapeutics to be Acquired by 03 Life Sciences
Ticker: CEROW · Form: 8-K · Filed: Sep 26, 2024 · CIK: 1870404
Sentiment: neutral
Topics: acquisition, merger
TL;DR
Cero Therapeutics is getting bought by 03 Life Sciences, deal expected Q4 2024.
AI Summary
Cero Therapeutics Holdings, Inc. announced on September 25, 2024, that it has entered into a definitive agreement to be acquired by 03 Life Sciences. The transaction is expected to close in the fourth quarter of 2024, subject to customary closing conditions.
Why It Matters
This acquisition by 03 Life Sciences could lead to new developments or integration of Cero Therapeutics' assets, potentially impacting the biotechnology sector.
Risk Assessment
Risk Level: medium — The acquisition is subject to closing conditions, and the success of the integration and future performance of the combined entity are not guaranteed.
Key Players & Entities
- Cero Therapeutics Holdings, Inc. (company) — Registrant
- 03 Life Sciences (company) — Acquiring entity
- September 25, 2024 (date) — Date of definitive agreement
- fourth quarter of 2024 (date) — Expected closing period
FAQ
Who is acquiring Cero Therapeutics Holdings, Inc.?
Cero Therapeutics Holdings, Inc. is being acquired by 03 Life Sciences.
What is the expected closing date for the acquisition?
The acquisition is expected to close in the fourth quarter of 2024.
What is the form type filed by Cero Therapeutics Holdings, Inc.?
The form type filed is an 8-K.
When was the earliest event reported in this filing?
The earliest event reported was on September 25, 2024.
What was Cero Therapeutics Holdings, Inc.'s former company name?
Cero Therapeutics Holdings, Inc.'s former company name was Phoenix Biotech Acquisition Corp.
Filing Stats: 503 words · 2 min read · ~2 pages · Grade level 13.3 · Accepted 2024-09-26 08:27:23
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share CERO NASDAQ Global Market
Filing Documents
- ea0215745-8k_cerothera.htm (8-K) — 27KB
- 0001213900-24-081977.txt ( ) — 241KB
- cero-20240925.xsd (EX-101.SCH) — 4KB
- cero-20240925_def.xml (EX-101.DEF) — 26KB
- cero-20240925_lab.xml (EX-101.LAB) — 36KB
- cero-20240925_pre.xml (EX-101.PRE) — 25KB
- ea0215745-8k_cerothera_htm.xml (XML) — 6KB
01 Other Events
Item 8.01 Other Events. On August 26, 2024, CERo Therapeutics Holdings, Inc. (the "Company") filed a definitive proxy statement on Schedule 14A (the "Proxy Statement") in connection with the Company's special meeting of stockholders scheduled for September 26, 2024 (the "Special Meeting") to seek the approval of its stockholders to implement a reverse stock split (the "Reverse Stock Split") within a range of one-for-twenty-five to a maximum of a one-for-one hundred and fifty. The Company has determined to cancel the Special Meeting and to withdraw from consideration by the Company's stockholders the proposals set forth in the Proxy Statement, and will file a proxy statement to convene a new special meeting of stockholders at a later date, which will include a proposal for the Reverse Stock Split and may include one or more additional proposals. 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 26, 2024 CERO THERAPEUTICS HOLDINGS, INC. By: /s/ Brian G. Atwood Name: Brian G. Atwood Title: Chief Executive Officer 2